Conference Coverage

Close joint health monitoring essential with new hemophilia therapies


 

FROM EAHAD 2021

Best practice

In the question-and-answer session following the talk, Fernando Zikan, MD, from the Federal University of Rio de Janeiro noted that, “in underdeveloped countries, we still find it very difficult to guide good practices for joint health control by the patient and family members. Which strategy do you think is fundamental for the patient to feel safe to notice changes in his body?”

“It would be useful to educate patients to come to the center whenever the patient has trauma and whenever an increase in his physical activity occurs. If this is far, a bedside ultrasound evaluation by the general practitioner could help avoid joint damage. Finally, a correct rehabilitation is fundamental,” Dr. Gualtierotti replied.

Asked by several others whether she used ultrasound in her daily practice, Dr. Gualtierotti said that “we use joint ultrasound in our clinical practice in the regular annual check-up examination and whenever the patient suspects and reports hemarthrosis.”

Dr. Gualtierotti reported participation in advisory boards for Biomarin, Pfizer, Bayer, and Takeda, and in educational seminars sponsored by Pfizer, Sobi, and Roche. She has received support for congress travel and/or attendance by Bayer and Pfizer. Dr. Zikan reported no relevant disclosures.

Pages

Recommended Reading

A 4-point thrombocytopenia score was found able to rule out suspected HIT
MDedge Hematology and Oncology
In COVID-19 patients, risk of bleeding rivals risk of thromboembolism
MDedge Hematology and Oncology
Von Willebrand disease guidelines address women’s bleeding concerns
MDedge Hematology and Oncology
Doctors search for missing link between COVID-19 and ITP
MDedge Hematology and Oncology
Immunoabsorption shows promise as an adjunct treatment for high-risk acquired hemophilia
MDedge Hematology and Oncology
Factor VIII concentrate is here to stay in hemophilia A
MDedge Hematology and Oncology
Safety profiles of hemophilia agents vary widely
MDedge Hematology and Oncology
Bleeding disorder diagnoses delayed by years in girls and women
MDedge Hematology and Oncology
Type 3 von Willebrand a rare but serious bleeding disorder
MDedge Hematology and Oncology
Joint pain in patients with hemophilia may be neuropathic
MDedge Hematology and Oncology